Analysis of anti-tumour necrosis factor-induced skin lesions reveals strong T helper 1 activation with some distinct immunological characteristics
- 16 November 2017
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 178 (5) , 1151-1162
Abstract
Background Psoriasiform and eczematous eruptions are the most common dermatological adverse reactions linked to anti‐tumour necrosis factor (TNF)‐α therapy. Yet, a detailed characterization of their immune phenotype is lacking. Objectives To characterize anti‐TNF‐α‐induced inflammatory skin lesions at a histopathological, cellular and molecular level, compared with psoriasis, eczema (atopic dermatitis) and healthy control skin. Methods Histopathological evaluation, gene expression (quantitative real‐time polymerase chain reaction) and computer‐assisted immunohistological studies (TissueFAXS) were performed on 19 skin biopsies from patients with inflammatory bowel disease (n = 17) and rheumatoid arthritis (n = 2) with new‐onset inflammatory skin lesions during anti‐TNF‐α‐therapy. Results Although most biopsies showed a psoriasiform and/or spongiotic (eczematous) histopathological architecture, these lesions were inconsistent with either psoriasis or eczema on a molecular level using an established chemokine (C‐C motif) ligand 27/inducible nitric oxide synthase classifier. Despite some differences in immune skewing depending on the specific histopathological reaction pattern, all anti‐TNF‐α‐induced lesions showed strong interferon (IFN)‐γ activation, at higher levels than in psoriasis or eczema. IFN‐γ was most likely produced by CD3/CD4/Tbet‐positive T helper 1 lymphocytes. Conclusions New‐onset anti‐TNF‐α‐induced eruptions previously classified as psoriasis or spongiotic dermatitis (eczema) exhibit a molecular profile that is different from either of these disorders.Keywords
Funding Information
- Austrian Society of Dermatology and Venereology
This publication has 57 references indexed in Scilit:
- The role of IL-22 and Th22 cells in human skin diseasesJournal of Dermatological Science, 2013
- Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatmentGut, 2013
- Anti-TNF-Alpha Induced Psoriasiform Eruptions with Severe Scalp Involvement and Alopecia: Report of Five Cases and Review of the LiteratureDermatology, 2012
- Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trialsBritish Journal of Dermatology, 2011
- Interferon-α in the generation of monocyte-derived dendritic cells: recent advances and implications for dermatologyBritish Journal of Dermatology, 2011
- Interferon-α-Conditioned Human Monocytes Combine a Th1-Orienting Attitude with the Induction of Autologous Th17 Responses: Role of IL-23 and IL-12PLOS ONE, 2011
- Eosinophilia during Psoriasis Treatment with TNF AntagonistsDermatology, 2011
- A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti–interferon-alfa monoclonal antibody, in subjects with chronic psoriasisJournal of the American Academy of Dermatology, 2010
- Cytokine imbalance with increased production of interferon-α in psoriasiform eruptions associated with antitumour necrosis factor-α treatmentsBritish Journal of Dermatology, 2009
- Flare and change of psoriasis morphology during the course of treatment with tumour necrosis factor blockersClinical and Experimental Dermatology, 2007